Logo

AstraZeneca and Hutchmed Initiate P-III SAMETA Trial of Imfinzi (durvalumab) + Orpathys (savolitinib) for Advanced Papillary Renal Cell Carcinoma

Share this

AstraZeneca and Hutchmed Initiate P-III SAMETA Trial of Imfinzi (durvalumab) + Orpathys (savolitinib) for Advanced Papillary Renal Cell Carcinoma

Shots:

  • The companies initiate P-III SAMETA study to evaluate the efficacy and safety of Hutchmed’s savolitinib (MET tyrosine kinase inhibitor) + AstraZeneca’s Imfinzi (PD-L1 inhibitor) in treatment-naïve patients with MET-driven advanced PRCC. The first patient was dosed on Oct 28, 2021
  • The 1EPs of the study is m-PFS & other EPs include m-OS, ORR, DoR, 6 & 12mos. DCR, time to second progression (PFS2), safety, PK, and QoL
  • In 2011, the companies collaborated to jointly develop & commercialize savolitinib where Hutchmed will lead marketing authorization, manufacturing & supply of the therapy in China & AstraZeneca is responsible for the commercialization globally

 

Ref: Globenewswire | Image: AstraZeneca

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions